Vnitr Lek 2024, 70(4):E21-E27

Amiodarone-induced thyropathies

Marianna Bystrianska1, Adrian Bystriansky2, Iveta Wildová1
1 II. interná klinika SZU, FNsP F. D. R. Banská Bystrica
2 II. klinika kardiológie SZU, Oddelenie arytmií SÚSCCH Banská Bystrica

Amiodaron is one of the most effective and widely used antiarrhythmics drug. It has an irreplaceable position in the treatment of ventricular tachycardia, the high content of iodine in its molecule predisposes it to the possible development of thyropathies. Amiodarone induced thyropathies, represent one of the serious complications of amiodarone treatment. The aim of the article is to provide a comprehensive review of the diagnosis, management and treatment of patients with amiodarone - induced thyropathies. The management of patient with amiodarone - induced thyrotoxicosis requires an interdisciplinary approach and a properly chosen treatment strategy. Patients with severe cardiac impairment and other comorbidities are often treated with amiodarone, which complicate the course of thyropathy and limit the terapeutic procedure. Therefore it is necessary to pay sufficient attention to their early diagnosis, clinical course and correctly selected therapy.

Keywords: amiodarone, thyropaties, thyrotoxicosis.

Accepted: June 12, 2024; Published: June 20, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Bystrianska M, Bystriansky A, Wildová I. Amiodarone-induced thyropathies. Vnitr Lek. 2024;70(4):E21-27.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Dan G, Martinez-Rubio A, Agewall S, et al. Antiarrhythmic drugs-clinical use and clinical decision making: A consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology, endorsed by the Hear. Europace. 2018;20(5):738. doi:10.1093/europace/euy119 Go to original source... Go to PubMed...
    2. Petr P, Verener M, Koeleman A. Amiodaron. Prvních čtyricet let. Journal of Applied Biomedicine. 2003:1-20. Go to original source...
    3. Júkič T, Punda M, Francechi M, et al. Amiodarone and the thyroid function. Lieči Vjesn. 2015;137:181-188
    4. Hrnčiar J. Osobitosti funkčných porúch štítnej žľazy (tyreotoxikóz a hypotyreóz), navodených jódom a jódovými preparátmi, hlavne amiodaronom. V: HRNČIAR, J. a kol.: Endokrinné a hormonálnometabolické choroby ich racionálna diagnostika a komplexná liečba. Centro Median 2000:119-125. ISBN: 80-968358-2-3
    5. Robertson RP, Giudice LC, Grossman AB, et al. DeGroot's Endocrinology: Basic Science and Clinical Practice. Press: Elsevier 2023:1389-1406. ISBN 978-0-323-69412-4.
    6. Herendael H, Dorien P. Amiodarone for the treatment and prevention of ventricular fibrillation and ventricular tachycardia. Vascular Health and Risk Management. 2010;6(1): 465-472. Available from: doi:10.2147/VHRM.S6611 Go to original source... Go to PubMed...
    7. Libby P, Bonow RO, Mann DL, et al. Braunwald's Heart Disease. A Textbook of Cardiovascular Medicine. 12 edition, Press: Elsevier 2021: 2034 p. ISBN 978-0-323-72219-3.
    8. Camm AJ, et al. Focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation * Developed with the special contribution of the European Heart Rhythm Association. European Heart Journal. 2012;33(21):2719-2747.
    9. Cahoon W, Flattery MP, Hess ML. Amiodarone: Development, Clinical Indications and Safety. Progress in Cardiovascular Nursing. 2007;173-176. Go to original source... Go to PubMed...
    10. Rao U, Agarwal A. Amiodarone-induced acute hepatotoxicity. European Journal of Clinical Pharmacology. 2011;68(4):449-450. Dostupné na: doi:10.1007/s00228-011-1126-0. Go to original source... Go to PubMed...
    11. Sloan RW. Cytochrome P-450. New Nomeclature and Clinical Implications. Clin Pharmacol Ther. 1996;61:201
    12. Medić F, Bakula M, Alfirević M, et al. Amiodarone and thyroid dysfunction. Acta Clin Croat. 2022;61(2):327-341. doi: 10.20471/acc.2022. 61. 02. 20. Go to original source...
    13. Tanda ML, Piantanida E, Lai A, et al. Diagnosis and management of amiodarone-induced thyrotoxicosis: similarities and differences between North American and European thyroidologists. Clinical Endocrinology. 2008;69(5):812-818. DOI:10.1111/j.1365-2265.2008.03268.x Go to original source... Go to PubMed...
    14. Tomisti L, Rossi G, Bartalena L, et al. The onset time of amiodarone-induced Thyreotoxicosis (AIT) depends on AIT type. European Journal of Endocrinology. 2014;171:363-368. Go to original source... Go to PubMed...
    15. Bartalena L, Brogioni S, Grasso L, et al. Interleukin-6: A marker of thyroid-destructive processes? Journal of Clinical Endocrinology and Metabolism.1994; 79(5):1424-1427. Go to original source... Go to PubMed...
    16. Trohman RG, Sharma PS, McAninch EA, Bianco AC. Amiodarone and thyroid physiology, pathophysiology, diagnosis and management. Trends Cardiovasc Med. 2019;29(5):285-295. Dostupné z DOI: 10.1016/j.tcm.2018. 09. 005. Go to original source...
    17. Bartalena L,Bogazzi F,Chiovato L, et al. European Thyroid Association (ETA) Guidelines for the Management of Amiodarone-Associated Thyroid Dysfunction. Eur Thyroid J. 2018 Mar;7(2):55-66. doi: 10.1159/000486957. Go to original source... Go to PubMed...
    18. Podoba J. Eufunkčná struma V: Kreze A, Langer P, Klimeš I et al. Všeobecná a klinická endokrinológia. Academic Electronic Press s.r.o., Bratislava, 2004; s. 219-228.
    19. Bogazzi F, Martino E, Dell'Unto E, et al. Thyroid color flow doppler sonography and radioiodine uptake in 55 consecutive patients with amiodarone-induced thyrotoxicosis. Journal of Endocrinological Investigation.2003;26(7):635-640. Go to original source... Go to PubMed...
    20. Shifrin AL, et al. Endocrine Emergencies. Edition 1st. Press: Elselvier 2022. 1-350. ISBN 987-0-323-76097-3.
    21. Hudzik B, Zubelewicz -Szkodzinska B. Amiodarone-related thyroid dysfunction. Internal and Emergency Medicin. 2014;9(8):829-839. Dostupné na: doi:10.1007/s11739-014-1140-1. Go to original source... Go to PubMed...
    22. Wanj J, Thang, Zhang R. Evaluation of 99mTc-MIBI in thyroid gland imaging for the diagnosis of amiodarone-induced thyrotoxicosis. Br. J. Radiol 2017 Mar;90(1071):20160836 Go to original source... Go to PubMed...
    23. Tsang W, Houlden RL. Amiodarone-induced thyrotoxicosis: a review. Can J Cardiol. 2009;25(7):421-4. Available from: DOI: 10.1016/s0828-282x(09)70512-4. Go to original source... Go to PubMed...
    24. O'Sullivan AJ, Lewis M, Diamond T. Amiodarone-induced thyrotoxicosis: left ventricular dysfunction is associated with increased mortality. Eur J Endocrinol. 2006;154(4):533-6. doi: 10.1530/eje.1.02122. PMID: 16556715. Go to original source... Go to PubMed...
    25. Podoba J, Zajacová H. Amiodaron a poruchy funkcie štítnej žľazy. Cardiology. 2000;9:20-24.
    26. Tsang W, Houlden RL. Amiodarone-induced thyrotoxicosis: a review. Can J Cardiol. 2009;25(7):421-4. Dostupné z DOI: 10.1016/s0828-282x(09)70512-4. Go to original source... Go to PubMed...
    27. Jabrocka-Hybel A, Bednarczuk T, Bartalena L, et al. Amiodarone and the thyroid. Endokrynol Pol. 2015;66(2):176-86. doi: 10.5603/EP.2015.0025. Go to original source... Go to PubMed...
    28. Vanderpump MP. Thyroid gland: use of glucocorticoids in amiodarone-induced thyrotoxicosis. Nat Rev Endocrinol. 2009;5(12):650-1. Available from: DOI: 10.1038/nrendo.2009.218. PMID: 19924150. Go to original source... Go to PubMed...
    29. Zhong B, Wnag Y, Zhang G, et al. Environmental Iodine Content, Female Sex and Age Are Associated with New-Onset Amiodarone-Induced Hypothyroidism: A Systematic Review and Meta-Analysis of Adverse Reactions of Amiodarone on the Thyroid. Cardiology. 2016;134(3):366-71. doi: 10.1159/000444578. Epub 2016 Apr 22. Go to original source... Go to PubMed...
    30. Stott DJ, Rodondi N, Kearney PM, et al. Trust Study Group. Thyroid Hormone Therapy for Older Adults with Subclinical Hypothyroidism. N Engl J Med. 2017;376(26):2534-2544. Available from: DOI : 10.1056/NEJMoa1603825. Go to original source... Go to PubMed...
    31. Benjamens S, Dullaartr RPF, Sluiter WJ, et al. The clinical value of regular thyroid function tests during amiodarone treatment. Eur J Endocrinol. 2017;177(1):9-14. doi: 10.1530/EJE-17-0018. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.